CTRI/2020/09/027513进行中（未招募）4 期
OPtical Coherence Tomography (OCT) Guided Coronary Stent IMplantation Compared to Angiography: a Multicenter Randomized TriaL in PCI ILUMIEN IV- OPTIMAL PCI - ILUMIEN IV- OPTIMAL PCI
Abbott India Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Pms
入排标准
入选标准
- •1. Subject must be at least 18 years of age.
- •2. Subject must have evidence of myocardial ischemia (e.g., stable angina, silent ischemia, unstable angina, or acute myocardial infarction) suitable for elective PCI.
- •3. Patients undergoing planned XIENCE stent implantation during a clinically indicated PCI procedure meeting one or more of the following criteria:
- •A) High clinical-risk, defined as;
- •Medication-treated diabetes mellitus, AND/OR
- •B) High angiographic-risk lesion(s), with at least one target lesion in each target vessel planned for randomization meeting at least one of the following criteria;
- •i. Target lesion is the culprit lesion responsible for either:
- •NSTEMI, defined as a clinical syndrome consistent with an acute coronary syndrome and a minimum troponin of 1 ng/dL (may or may not have returned to normal), and >1 mm ST segment deviation and/or dynamic T wave changes at rest within 7 days, OR
- •STEMI >24 hours from the onset of ischemic symptoms
- •ii. long or multiple lesions (defined as intended total stent length in any single target vessel >=28 mm),
- •iii. bifurcation intended to be treated with 2 planned stents (i.e. in both the main branch and side branch), and where the planned side branch stent is >= 2.5 mm in diameter.
- •iv. angiographic severe calcification (defined as angiographically visible calcification on both sides of the vessel wall in the absence of cardiac motion),
- •v. chronic total occlusion (CTO) (enrolment and randomization in this case performed only after successful antegrade wire escalation crossing and pre-dilatation)
- •vi. in-stent restenosis (all patterns, as long as the lesion is at or within the stent margin(s) and has an angiographically visually-assessed DS >=70% or DS >=50% with non-invasive or invasive evidence of ischemia)
- •4. All target lesions (those lesions to be randomized) must have a visually estimated or quantitatively assessed %DS of either >=70%, or >=50% plus one or more of the following: an abnormal functional test (e.g. fractional flow reserve, stress test) signifying ischemia in the distribution of the target lesion(s) or biomarker positive ACS with plaque disruption or thrombus.
- •5. All target lesions must be planned for treatment with only >=2.5 mm and <=3.5 mm stents and post-dilatation balloons based on pre-PCI angiographic visual estimation. The only exception is for long target lesions (visually estimated as >20 mm), in which after implantation of a <=3.5 mm stent up to half of the stented segment may be post-dilated with balloons >3.5 mm as needed per operator judgment.
- •For example, if there is a 34 mm long LAD lesion spanning the proximal and mid segments, a 38 mm long 3.0 mm diameter Xience stent may be implanted, and the proximal half of the stent may be post-dilated with a 3.75 mm balloon.
- •6. No more than 2 target lesions requiring PCI are present in any single vessel., and no more than 2 target vessels are allowed. Thus, up to 4 randomized target lesions per patient in a maximum of 2 target vessels are allowed, including branches. The intended target lesions will be declared just prior to randomization.
- •Note: A lesion is defined as any segment(s) of the coronary tree, no matter how long, which is planned to be covered with one contiguous length of stent, whether single or overlapped. A bifurcation counts as a single lesion even if the side
排除标准
- •Clinical exclusion criteria:
- •1. STEMI <=24 hours from the onset of ischemic symptoms
- •2. Creatinine clearance <=30 ml/min/1.73 m2 (as calculated by MDRD formula for estimated GFR)5 and not on dialysis. Note: chronic dialysis dependent patients are eligible for enrolment regardless of creatinine clearance.
- •3. Hypotension, shock or need for mechanical support or intravenous vasopressors
- •4. CHF (Killip class >=2 or NYHA class >=3)
- •5. LVEF <=30% by the most recent imaging test within 30 days prior to procedure (echo, MRI, contrast left ventriculography or other)
- •6. Unstable ventricular arrhythmias
- •7. Inability to take DAPT (both aspirin and a P2Y12 inhibitor) for at least 12 months in the patient presenting with an ACS, or at least 6 months in the patient presenting with stable CAD, unless the patient is also taking chronic oral anticoagulation in which case a shorter duration of DAPT may be prescribed per local standard of care.
- •8. Planned cardiac or non-cardiac surgery within 24 months after the index procedure
- •9. Prior PCI within the target vessel within 12 months (unless the target lesion is the prior PCI site - i.e. in-stent restenosis)
- •10. Any planned PCI within the target vessel(s) within 24 months after the study procedure, other than a planned staged intervention in a second randomized target vessel.
- •Note: Planned staged interventions must be noted at the time of randomization, and the decision to stage may be modified within 24 hours of completion of the index PCI. See Section 6.5.3.7 for more details of multi lesion and vessel treatment.
- •Note: PCI in non-target vessels is permitted >48 hours after the index procedure.
- •11. Any prior PCI in a non-target vessel within 24 hours before the study procedure, or within previous 30 days if unsuccessful or complicated.
- •Note: Patients requiring non-target vessel PCI may be enrolled and the non-target vessel(s) may be treated in the same index procedure as the randomized lesions (in all cases prior to randomization), as long as treatment of the lesion(s) in the non-target vessel is successful and uncomplicated.
- •Successful and uncomplicated definition for non-target vessel treatment during the index procedure: Angiographic diameter stenosis <10% and TIMI III flow (visually assessed) for all non-target lesions and vessels, without dissection >= NHLBI type C, perforation, prolonged chest pain ( >5 minutes) or prolonged ST-segment elevation or depression ( >5 minutes), or cardiac arrest or need for defibrillation or cardioversion or hypotension /heart failure requiring mechanical or intravenous hemodynamic support or intubation.
- •12. Subject has known hypersensitivity or contraindication to any of the study drugs (including heparin and all P2Y12 inhibitors, one or more components of the study devices, including everolimus, cobalt, chromium, nickel, platinum, tungsten, acrylic and fluoropolymers, or radiocontrast dye that cannot be adequately pre-medicated.
- •13. Subject has received any solid organ transplants or is on a waiting list for any solid organ transplants.
- •14. Subject is receiving immunosuppressant therapy or has known immunosuppressive or severe autoimmune disease that requires chronic immunosuppressive therapy (e.g., human immunodeficiency virus, systemic lupus erythematosus, etc.). Note: corticosteroids are not included as immunosuppressant therapy. <br/
研究者
相似试验
已完成
不适用
OPtical Coherence Tomography (OCT) Guided Coronary Stent IMplantation Compared to Angiography: a Multicenter Randomized TriaL in PCINL-OMON54677St. Jude Medical1,096
进行中（未招募）
不适用
ILUMIEN IV: OPTIMAL PCICoronary Artery DiseaseJPRN-jRCT1032200080Coe Jessie3,656
已完成
不适用
Optical CoherenCe tomography-gUided coronary intervention in Patients with complex lesIons: a randomized controlled trial (OCCUPI trial)KCT0003325Yonsei University Health System, Severance Hospital1,604
尚未招募
不适用
Does detailed imaging of buildup in the heart arteries improve prediction of future heart problems in patients hospitalised with heart attack.Myocardial infarctionACTRN12618001680257Abbott Vascular582
已完成
不适用
Quantitative coronary optical coherence tomography analysis for signal attenuation and intensityThe patients who underwent coronary optical coherence tomography study for the evaluation of restenosis tissueJPRN-UMIN000003510Division of Cardiology, Teikyo University Hospital17